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Numerous risk tools are now available, which predict either current or future risk of a cancer diagnosis. In theory, these tools
have the potential to improve patient outcomes through enhancing the consistency and quality of clinical decision-making,
facilitating equitable and cost-effective distribution of finite resources such as screening tests or preventive interventions, and
encouraging behaviour change. These potential uses have been recognised by the National Cancer Institute as an ‘area of
extraordinary opportunity’ and an increasing number of risk prediction models continue to be developed. The data on
predictive utility (discrimination and calibration) of these models suggest that some have potential for clinical application;
however, the focus on implementation and impact is much more recent and there remains considerable uncertainty about their
clinical utility and how to implement them in order to maximise benefits and minimise harms such as over-medicalisation,
anxiety and false reassurance. If the potential benefits of risk prediction models are to be realised in clinical practice, further
validation of the underlying risk models and research to assess the acceptability, clinical impact and economic implications of
incorporating them in practice are needed.
A risk prediction model aims to predict the probability or risk of a
condition or event among individuals, or occasionally groups,
based on a combination of known or measured characteristics. Risk
prediction tools are the means by which risk prediction models,
scores or algorithms are implemented in clinical practice.
Numerous risk tools are now available, which predict either
current or future risk of a cancer diagnosis. In theory, these tools
have the potential to improve patient outcomes through enhancing
the consistency and quality of clinical decision-making, facilitating
equitable and cost-effective distribution of finite resources and
encouraging behaviour change. These potential uses have been
recognised by the National Cancer Institute as an ‘area of
extraordinary opportunity’ (National Cancer Institute, 2006) and
an increasing number of risk prediction models continue
to be developed. In the near future, risk prediction models are
also likely to incorporate genomic data and could contribute
to the translation of precision or personalised medicine and
precision screening into clinical practice. However, there remains
uncertainty about the clinical utility of risk tools and how to
implement them to maximise benefits and minimise harms such as
over-medicalisation, anxiety and false reassurance. In this study we
provide an overview of the types of risk prediction models that exist,
their potential uses, the existing evidence around their use, the
challenges to implementation and the key issues for future research
(see Box 1).
Box 1. Sources and selection criteria
To prepare this review we searched Medline, Embase, reference lists of major
reviews and personal records using the terms ‘cancer’, ‘risk model’ or ‘risk
prediction’ and ‘primary care’ or site-specific cancer terms. We focused on
systematic reviews, meta-analyses, randomised controlled trials and
observational studies in primary care.
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WHAT TYPES OF RISK PREDICTION MODELS EXIST?
Although there is some overlap, the two main types of risk
prediction model for cancer in primary care are as follows:
(1) To predict the risk of prevalent but undiagnosed disease in
those with symptoms.
(2) To predict the risk of future incident disease in asymptomatic
individuals.
Models that predict the risk of current cancer in individuals
with symptoms are principally designed to guide further
investigation and referral. Many have been developed for a range
of cancers; in the United Kingdom the best known are the risk
assessment tools (RATs) developed from case–control studies in
primary care (Hamilton, 2009) and the QCancer series derived
from cohorts from primary-care electronic health records
(e.g., Hippisley-Cox and Coupland, 2015; Box 2).
Models that predict risk of future incident cancer are designed
to identify individuals at higher risk of disease before development
of symptoms. Since the first of these for cancer was described—for
breast cancer in 1989—several hundred have been developed
for breast and other cancers. These include at least 25 risk models
for melanoma (Usher-Smith et al, 2014), 17 for breast cancer
(Meads et al, 2012), 4 for lung cancer (Li et al, 2015), 127 for
prostate cancer (Louie et al, 2014) and 9 for colorectal cancer
(Win et al, 2012). Examples of those that have been externally
validated for each of these cancers are given in Table 1.
HOW ARE RISK PREDICTION MODELS DEVELOPED AND
EVALUATED?
Most are developed by applying multivariate statistical methods,
usually logistic or Cox regression modelling, to data from
epidemiological studies. Ideally, these are prospective cohort
studies. Many of the well-known risk prediction models, however,
have been developed using case–control designs either with
concurrent data collection or retrospective risk factor information
from electronic health records. A number of well-known models,
including the Disease Risk Index developed by the Harvard School
of Public Health (Colditz et al, 2000), have also used systematic
reviews of existing studies and expert opinion.
When evaluating risk models, there are two main aspects to
consider. The first is how well the model predicts the relevant
outcome in the population of interest (the predictive performance)
(Steyerberg et al, 2013; Collins et al, 2015). This is assessed by
estimating the following: the discrimination or ability to rank
individuals (e.g., sensitivity, specificity and area under the receiver
operating characteristic curve (AUROC)); the calibration or ability
to predict the absolute level of risk (e.g., calibration plots of
observed vs predicted risk and the Hosmer–Lemeshow w2-test);
and the model fit or whether the model predicts disease better than
chance alone (e.g., the Bayes information criterion). Ideally, risk
models are developed in one population-based data set and
externally validated in a second independent population-based
data set, because predictive utility tends to be overestimated when
models are tested in the same population in which they were
developed (Collins et al, 2015). However, if this is not possible, re-
sampling methods such as bootstrapping can be used to assess
possible optimism in model performance: these methods are
preferable to splitting the data into development and validation
samples (Steyerberg et al, 2013). Over-optimism (or spectrum
effect or bias) also occurs when the frequency of the outcome is
inflated in development or validation samples, for example, in
case–control studies in which the frequency of cancer may be 50%.
This must be taken into account when considering application of a
risk model to a different population.
The second aspect is whether the use of the risk tool influences
clinician or patient behaviour and patient outcomes. This is
addressed through implementation studies, ideally randomised
controlled trials (RCTs), in which clinical and patient behaviour,
patient outcomes and cost effectiveness can be assessed.
HOW CAN THE INFORMATION DERIVED FROM RISK
PREDICTION MODELS BE USED?
Once developed and evaluated, these models can be incorporated
into risk prediction tools and provided on paper, as mouse mats or
flipcharts, or as electronic tools, either integrated into clinical
computer systems or as standalone/web-based electronic tools such
as the Disease Risk Index developed by the Harvard School of
Public Health (available at http://www.diseaseriskindex.harvar-
d.edu). The output can be presented either as absolute or relative
risk, rank or peer comparison, with more sophisticated tools
presenting risk in a variety of formats along with the potential
impact of risk-reducing interventions.
For patients with symptoms, these tools can then be used to
help guide investigation and referral. For example, working in
collaboration with Macmillan Cancer Support, BMJ Informatica
has developed the electronic Cancer Decision Support Tool,
which integrates both the RATs and QCancer models (Box 1)
within general practice computer systems to provide three
functions for GPs:
Box 2. Details of the RATs and QCancer series risk
prediction tools for symptomatic individuals
The Risk Assessment Tools
 Designed to be used in symptomatic populations presenting to
primary care.
 Developed from case–control studies in UK primary care.
 So far, tools for 14 separate cancer sites have been published
(colorectal, oesophageal, lung, ovarian, kidney, bladder, pancreas,
breast, uterine, brain, prostate, Hodgkin lymphoma, non-Hodgkin
lymphoma and multiple myeloma).
 Provide risk estimates for patients with single symptoms of possible
cancer, pairs of symptoms and repeat attendances with the same
symptoms.
The QCancer series
 Hybrid models that can be used both in symptomatic and asympto-
matic populations.
 Developed in the QRESEARCH database, a large database compris-
ing over 12 million anonymised health records from 602 general
practices throughout the United Kingdom using the EMIS
(Egton Medical Information Systems) computer system.
 Six models have been published for symptomatic populations
(for colorectal, gastro-oesophageal, lung, renal, pancreatic and
ovarian cancer), plus models predicting risk for multiple cancers for
males and females.
 Provide estimates of absolute risk of any cancer with a breakdown of
type of cancer based on both risk factors such as age, gender and
family history, which increase the likelihood of cancer, and risk
markers such as haemoptysis or weight loss, which are features,
usually symptoms, suggesting that cancer is already present.
 Available on line at www.qcancer.org
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(1) Prompts during consultations if patients have a risk of X2%
(adjustable) for lung, colorectal, pancreatic, ovarian or
oesophago-gastric cancer, using information added as
Read-codes in the past;
(2) A series of ‘symptom checkers’ for patients in whom GPs have
identified symptoms suggestive of cancer, which enable them
to enter additional symptomatic information and update the
cancer risk estimates;
(3) A risk stratification tool intended for use separately from
consultations. Working as an audit tool, it allows practices to
generate lists of all registered patients in whom a risk score can
be calculated and sorts them by cancer type and risk category.
By stratifying the population into different risk levels, risk
prediction tools for asymptomatic individuals have the potential
not only to identify people for tailored cancer screening, behaviour
change programmes and preventive treatment but also to allocate
finite preventive resources more efficiently than by age and gender
alone. They may also provide opportunities to motivate behaviour
change among both healthcare professionals and patients, including
discussions around lifestyle factors, uptake of cancer screening and
potential chemo-prophylactic options, such as the use of aspirin in
those at higher risk of colorectal cancer or hormone modification
for breast cancer. Even for well-established cardiovascular risk
tools, however, there is little evidence that simply providing
patients with a number (Brindle et al, 2006) or genetic risk
(Marteau et al, 2010) leads to significant changes in habitual and
environmentally cued behaviours such as diet, smoking, physical
activity and alcohol intake; whether providing risk information on
future cancer risk will have greater effects is as yet unknown.
What current evidence is there for risk prediction tools for
cancer?
Tools for predicting the risk of prevalent undiagnosed cancer in
symptomatic individuals. Many of the risk models for symptomatic
individuals have been validated in separate populations. These
include several of the QCancer risk models (e.g., Collins
and Altman, 2013) and the colorectal cancer RAT (Marshall et al,
2011), as well as other well-known models such as the Selvachan-
dran model for colorectal cancer (Selvachandran et al, 2002). These
show that the models have good discrimination with AUROCs
between 0.79 and 0.95, and sensitivities of 46.0–61.3 with a
specificity of 95%.
By comparison, to our knowledge, there have been no published
RCTs of implementation. Several feasibility studies of the QCancer
or RAT models have been reported. In one, the clinical utility of
two RATs (colorectal and lung) was assessed in 165 practices
(Hamilton et al, 2013). Paper, mouse mat and desktop easel forms
were provided for a 6-month period. During this time there was an
increase in cancer diagnostic activity, urgent referrals and cancer
diagnoses when compared with the previous 6 months. However,
as this was not a trial, it is not possible to say whether these
changes were due to the use of the RATs or whether they were
clinically appropriate. An embedded qualitative study showed that
the majority of GPs found the RATs useful in consultations and
their use heightened GPs’ awareness of potential cancer symptoms,
reminded and alerted them to potential cancer risks and affected
their thresholds (Green et al, 2014). Another qualitative study
explored GP views following implementation of the same two
RATs (colorectal and lung) in an electronic format (eRATs)
(Dikomitis et al, 2015). This also showed that the tools raised
awareness of potential cancer symptoms among GPs and affected
their referral thresholds. However, there was concern about
‘prompt fatigue’ whereby GPs became inured to (or irritated by)
recurrent prompts, the reliance of the tool on Read codes—which
are used very differently by different GPs—and the medico-legal
implications of having access to a list of patients with increased risk
and not acting on it.
Tools for predicting the risk of future incident cancer in
asymptomatic individuals. Considering the number and range
of risk models for predicting risk of cancer in asymptomatic
individuals, few have been validated in external populations; in
recent systematic reviews, only 2 out of 25 risk models for
melanoma (Usher-Smith et al, 2014), 6 out of 17 risk models for
breast cancer (Meads et al, 2012) and 6 out of 9 for colorectal
cancer (Win et al, 2012) have been validated in external
populations, and only 6 of the 127 models for prostate cancer
have been validated in X5 external populations with a reported
C-statistic (Louie et al, 2014).
The performance, and therefore potential utility, of these models
varies, in part because of different selected cut-offs for high-risk
groups, but several have C-statistics over 0.7 (Table 1). As with the
tools for symptomatic individuals, few of these risk tools have been
subject to RCTs, to assess their clinical impact (Marteau et al, 2010;
Walker et al, 2015). Your Disease Risk (YDR), based on the
Harvard risk model, has been evaluated as part of a decision aid for
colorectal cancer screening (Schroy et al, 2012). The group that
received the decision aid alone had higher colorectal screening
rates compared with either the control group or the group that
received YDR plus the decision aid. The other large primary-care
trials of risk tools for prevention have focused on family history as
Table 1. Examples of risk prediction models for asymptomatic
individuals that have been validated in different populations
Summary of performance in validation studies
Risk model
Discrimination
(AUROC, 95% CI)
Calibration
(O/E, 95% CI)
Breast (Meads et al, 2012)
Colditz 0.63 (0.63–0.64) 1.01 (0.94–1.09)
Gail 2 0.63 (0.59–0.67) 0.95 (0.88–1.01)
Rosner and Colditz 0.57 (0.55–0.59) 0.96 (0.92–1.02)
Tyrer and Cusick 0.762 (0.70–0.82)a 1.09 (0.85–1.41)a
Lung (Li et al, 2015)
Bach 0.81 (0.76–0.86) 0.88 (0.72–1.08)
Sptiz 0.78 (0.73–0.83) 3.75 (3.06–4.60)
LLP 0.79 (0.73–0.83) 1.12 (0.92–1.37)
PLCOM2012
b 0.81 (0.76–0.86) 1.03 (0.87–1.23)
Colorectal (Win et al, 2012)
Harvard Cancer
Risk Index
Men: 0.71 (0.68–0.74)
Women: 0.67 (0.64–0.70)
—
Imperiale 0.74 (SD¼ 0.06) —
Freedman Men: 0.61 (0.60–0.62)
Women: 0.61 (0.59–0.62)
Men: 0.99 (0.95–1.04)
Women: 1.05 (0.98–1.11)
Ma 0.64 (0.61–0.67) 1.09 (0.98–1.23)
Prostate (Louie et al, 2014)
Prostataclass 0.79 (0.75–0.84) —
Finne 0.74 (0.70–0.77) —
Karakiewcz 0.74 (0.69–0.80) —
Prostate Cancer
Prevention Trial
0.66 (0.63–0.68) —
Chun 0.76 (0.72–0.79) —
ERSPC RC3c 0.79 (0.77–0.81) —
Melanoma (Usher-Smith et al, 2014)
Fortes 0.79 (0.70–0.86) —
Williams 0.70 (0.64–0.77)
Abbreviations: AUROC¼ area under receiver operator characteristic curve; CI¼ confidence
interval; LLP, liverpool lung project; O/E¼ ratio of observed to expected events.
aIn a high-risk sample.
bThe 2012 version of the prostate, lung, colorectal, and ovarian cancer screening trial
model.
cEuropean Randomized Study of Screening for Prostate Cancer Risk Calculator 3.
Risk prediction tools for cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.409 1647
the principal risk factor. The GRAIDS Trial was a cluster RCT in
the United Kingdom examining a web-based family history RAT
for breast, ovarian and colorectal cancer (Emery et al, 2007).
Risk was assessed using risk-assessment guidelines; participants
were also provided with numerical estimates for breast cancer risk
using the Claus model (Claus et al, 1991). Practices that received
the GRAIDS software showed significant increases in referral rates
and more appropriate referrals to cancer genetics services
compared with those that received education and the paper
guidelines. However, because of limited specificity of the
risk-assessment guidelines, the GRAIDS software resulted in
over-referral of people with a family history of colorectal cancer.
The Family Healthware Impact Trial in the United States also
tested a web-based risk assessment tool aimed for use by
consumers. It assessed risk of common cancers, heart disease
and type 2 diabetes using family history risk heuristics giving
tailored health preventive messages (Ruffin et al, 2011). Those
receiving the intervention were significantly more likely to increase
their self-reported physical activity and intake of fruit and
vegetables to recommended levels than the control group, who
received standardised health messages. No differences in cancer
screening rates between groups were observed, although rates at
baseline were relatively high in both groups.
What are the main challenges to implementation of risk
prediction tools for cancer in primary care?
Choosing which risk model to use. The choice of risk model is of
particular importance when used to predict future risk of disease in
asymptomatic individuals. Some models include personal informa-
tion, such as naevi count, dietary factors or genetic information,
requiring some form of initial data collection, whereas others
include only data routinely collected during clinical care, such as
BMI and smoking status, and thus can be implemented with little
additional resource. Although some are targeted at the general
population, others include results from screening tests (such as
faecal occult blood tests) and so are more applicable to a stratified
risk-assessment programme. The sensitivity and specificity of the
models also vary. For melanoma, for example, risk models range
from those in which 50% of the population would be classified
as high risk and 80% of melanomas would be detected from that
high-risk group, to those in which only 20% would be identified as
high risk and only 50% of cases would be detected (Usher-Smith
et al, 2014). The choice for a given setting and health system is
likely to be driven by practical and financial constraints, and the
relative benefits, harms and costs of missed and over-diagnoses.
Choosing when and where risk should be predicted. When
considering implementing risk tools for asymptomatic individuals,
the challenge is to balance the benefits and harms, and
demonstrate cost effectiveness. Systematic application of a risk
tool to an entire population could be used to identify populations
at increased risk of a cancer, who could then be offered tailored
screening and primary preventive advice. It is likely to be that the
use of risk prediction tools would identify those at higher risk with
greater discrimination and accuracy than current simple guide-
lines, although recent UK guidelines were based in part on data
within risk tools. However, any potential reduction in cancer
incidence for a small proportion of the population needs to be
balanced against possible net harms (anxiety and false reassurance)
among the majority, as well as the cost of implementation and
additional health care use by ‘medicalised’ or ‘overdiagnosed’
members of the population. As research advances into possible
chemo-preventive agents such as aspirin, to reduce future risk of
colorectal cancer, the potential side effects of medication and the
risks of over-medicalisation need to be considered as well.
Understanding and overcoming barriers to use. For the tools
designed for symptomatic individuals the main challenges are
finding ways to make the tools accessible for clinicians and
presenting risk information in an understandable format. Recent
research has shown that clinicians may interpret symptoms
inconsistently (Chiang et al, 2015), leading to inaccurate and
unreliable cancer risk assessment, and although GPs were able to
make sense of the purpose of the tool, they found the tool difficult
to introduce into the workflow of the consultation. They may also
be reluctant to use the tools for fear of alarming their patients if the
risk information is presented too explicitly (Chiang et al, 2015). We
also know from work around the use of tools that predict future
risk of cardiovascular disease that lack of time, poor knowledge or
understanding of the tools, the perception that clinical judgement
is as good as or better than risk tools, uncertainty about how to
account for risk factors perceived to be important but not included
in the tools and poor computer software all form barriers to use
(Van Steenkiste et al, 2004; Mu¨ller-Riemenschneider et al, 2010).
Communicating the risk. The format in which risk information is
presented is a key aspect of risk assessment tools, as it affects both
clinicians’ use of the tool and patients’ understanding and
perception of risk. A recent study with GPs and simulated
consultations using a tool that implemented QCancer suggested
that GPs may prefer traffic-light colour coding of risks (red, amber
and green) with secondary access to the numeric risks, if needed,
rather than absolute numeric risks or being presented with
diagnostic guidance as the primary output (Chiang et al, 2015).
It is likely to be that GPs will differ in their preferences;
furthermore, these may change over time and with different
patients.
It is also not clear how best to present this risk information to
patients. From the field of cardiovascular disease we know that
numerical presentation of risk—as opposed to simple risk
categories—and timeframes o10 years lead to more accurate risk
perceptions. Conversely, presenting relative risk reductions
maximises acceptance of treatment and ‘heart age’ appears to
increase intention to change behaviour (Waldron et al, 2011).
Research is needed to see whether this is the same for cancer risk
and to assess the impact of recent developments; these include
expected frequency trees (Kurz-Milcke et al, 2008) that could
potentially be of benefit when there are concerns about potential
overscreening in people at average cancer risk.
Deciding where to set the thresholds for intervention. This is
perhaps the biggest challenge for all cancer risk tools. With the
current drive for earlier diagnosis of cancer in primary care, it is
tempting to choose a low threshold for tools for symptomatic
patients so that few individuals with cancer are missed. However,
as always, there is a trade-off between sensitivity and specificity:
although cancer risk prediction tools have the potential to enable
better case selection for screening, preventive programmes and
investigation for suspected cancer, they can also lead to
overinvestigation, overdiagnosis and unnecessary harmful treat-
ment, in particular for asymptomatic screened populations.
Although their use can potentially make cancer screening more
cost-effective (Chowdhury et al, 2013), all screening programmes
cause harm and the selection of cut-offs at which to change the
nature or frequency of screening will have financial and resource
implications.
CONCLUSIONS
Following in the footsteps of cardiovascular risk scores, numerous
tools are now being made available in primary care to estimate,
communicate and monitor risk of current undiagnosed and future
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incident cancer. The data on predictive utility (discrimination and
calibration) of these models suggest that some have potential for
clinical application. However, the focus on implementation and
impact is much more recent, with considerable uncertainty about
their clinical utility and how best to implement them in primary
care, in order to maximise benefits and minimise harms. To ensure
we make the most of this ‘area of extraordinary opportunity’,
future research therefore needs to focus on the following: wider
validation of the underlying risk models; assessment of the utility,
including patient and professional acceptability, of incorporating
them into risk tools in practice; impact studies addressing whether
their use affects behaviour of either patients or practitioners; and
studies modelling the population level impact and economic
implications of widespread use.
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